Leading clinical immunology into its next chapter.

HI-Bio™ leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases (IMDs). With clinical-stage programs and pipeline, HI-Bio has the potential to address diseases across the immune landscape.

Press Release

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

View More